Tradestie Institutional Equity Comparison Engine · Market Close Apr 24, 2026

AKRO vs FOLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FOLD Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

FOLD Overall Winner 6-Pillar Tally: AKRO 0 – 6 FOLD Matrix Metrics: AKRO 2 – 8 FOLD

As of Apr 24, 2026, Amicus Therapeutics, Inc (FOLD) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas FOLD carries 59.4/100 (HOLD) at $14.49 (17.7x Forward P/E, 8.6% operating margin).

  • Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. FOLD 59.4/100 HOLD), FOLD captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.6% vs. 0.0% operating margin) and revenue trajectory (+23.7% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKRO vs FOLD
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91
FOLD NASDAQ Head-to-Head Winner
Amicus Therapeutics, Inc
Pharmaceutical Preparations
$14.49
+0.21% 1D
Market Cap $4.5B
TTM Revenue $634M
Forward P/E 17.7x
Beta / 30D Vol 0.27β · 2% Vol
Unified Composite Score
59.4 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 71.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 70
RSI-14: 70.4 · SMA20: $14.46 · SMA50: $14.40

6-Pillar Scorecard Institutional Category Breakdown (AKRO 0 – 6 FOLD)

Columns: Metric · AKRO · FOLD
1. Valuation Multiples FOLD
Forward P/E N/M 17.7x
Trailing P/E N/M 30.5x
PEG Ratio N/M N/M
EV / Revenue N/M 7.2x
2. Growth & Scale FOLD
Revenue Growth (YoY) +0.0% +23.7%
Earnings Growth (YoY) +0.0% -95.5%
TTM Revenue (USD) N/A $634M
Market Cap $4.5B $4.5B
3. Profitability & Quality FOLD
Gross Margin N/A 88.5%
Operating Margin 0.0% 8.6%
Net Profit Margin 0.0% -4.3%
Return on Equity (ROE) -34.5% -11.6%
4. Balance Sheet & Cash Flow FOLD
Cash Generation (TTM) N/A $42M EBITDA
Cash Flow Margin N/A 6.6% EBITDA Mgn
Net Cash / Leverage $11.95 Book/Sh · -34.5% ROE $0.88 Book/Sh · -11.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FOLD
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 7.3% (30th %ile) 0.2% (<1st %ile)
Put/Call OI Skew N/A 0.03x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat FOLD
OpEx & R&D Intensity N/A 79.9% of Rev ($507M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Pharmaceutical Preparations Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKRO (2) vs FOLD (8)
Institutional Metric AKRO FOLD Criterion Row Edge
Market Capitalization
Scale
$4.5B $4.5B Larger Scale FOLD
Trailing P/E Ratio
Valuation
N/M 30.5x Lower Multiple FOLD
Forward P/E Ratio
Valuation
N/M 17.7x Lower Multiple FOLD
Revenue Growth (YoY)
Growth
+0.0% +23.7% Higher Growth FOLD
Operating Margin (TTM)
Profitability
0.0% 8.6% Higher Margin FOLD
Net Profit Margin
Profitability
0.0% -4.3% Higher Margin AKRO
Return on Equity (ROE)
Capital Efficiency
-34.5% -11.6% Higher ROE FOLD
52-Week Range Position
Momentum
90% ($21–$58) 100% ($6–$14) Stronger Trend FOLD
Beta / 30D Volatility
Risk Regime
0.90β · 2% Vol 0.27β · 2% Vol Lower Realized Risk FOLD
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 59.4 / 100 (HOLD) Higher Composite AKRO
Trailing 12M Revenue (USD)
Operating Scale
N/A $634M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 88.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.95 Book/Sh · -34.5% ROE) $42M EBITDA ($0.88 Book/Sh · -11.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FOLD +9.3 pp
AKRO: +1.37% · FOLD: +10.67%
3M Horizon FOLD +2.36 pp
AKRO: +22.48% · FOLD: +24.84%
6M Horizon FOLD +63.46 pp
AKRO: -0.11% · FOLD: +63.35%
1Y Horizon FOLD +0.76 pp
AKRO: +37.97% · FOLD: +38.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs FOLD. Trailing 12-month operating profitability (AKRO 0.0% vs FOLD 8.6%) and valuation multiples (AKRO N/M vs FOLD 17.7x Forward P/E) are benchmarked directly in Pillar 4 below.

AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M
FOLD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$634M
Gross Margin88.5%
Op. Margin8.6%
ROE / Fwd P/E-11.6% · 17.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.2%
IV Percentile <1st %ile
Put/Call OI Skew 0.03x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact FOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.5B market capitalization and 8.6% operating margin.
OpEx & R&D Reinvestment 79.9% of Rev ($507M)
90D Engineering Disclosures 0 Published

Investor FAQ AKRO vs FOLD Key Questions & Quantitative Answers

As of Apr 24, 2026, Amicus Therapeutics, Inc (FOLD) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas FOLD carries 59.4/100 (HOLD) at $14.49 (17.7x Forward P/E, 8.6% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. FOLD 59.4/100 HOLD), FOLD captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.6% vs. 0.0% operating margin) and revenue trajectory (+23.7% vs. +0.0% YoY).

FOLD leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FOLD at +23.7% YoY revenue growth and -95.5% YoY earnings growth on $634M TTM revenue (88.5% gross margin, 8.6% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $634M for FOLD. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus 79.9% of Rev ($507M) (0 disclosures) for FOLD.

FOLD screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FOLD trades at 17.7x Forward P/E, 30.5x Trailing P/E, N/M PEG, and 7.2x EV/Revenue (6.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus FOLD (-11.6% ROE) capital efficiency.

In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, FOLD carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Apr 24, 2026. For educational research only; not investment advice.